|Bid||5.20 x 800|
|Ask||5.54 x 1300|
|Day's Range||5.47 - 5.58|
|52 Week Range||4.82 - 7.73|
|Beta (3Y Monthly)||0.18|
|PE Ratio (TTM)||18.94|
|Earnings Date||Feb 28, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
NEW YORK, Aug. 7, 2019 /PRNewswire/ -- The Seiden Group, a law firm headquartered in New York, representing a shareholder group of Global Cord Blood Corporation (NYSE: CO) (the "Company" or "Global Cord") issued a third letter yesterday to Global Cord, which was addressed to the Compensation Committee of the Board of Directors. In the letter, the shareholder group also urged the Compensation Committee to fulfill its obligation to the Company and its shareholders, as described in its most recent 20-F filed with the SEC, to replace the underperforming executives who have not created shareholder value over the past ten years and hire a new team to lead the Company.
(Bloomberg) -- A case brought by a U.S. hedge fund against China’s Global Cord Blood Corp. may set a precedent in the Cayman Islands for other minority shareholders who feel shortchanged by all-share mergers.Jayhawk Capital Management LLC and founder Kent McCarthy have sued the company and three of its directors, claiming a proposed $915 million all-share merger would reduce the value of their holdings. They are asking the Grand Court of the Cayman Islands to declare they can object to the deal, and have the right to ask the court to determine the fair value of their shares, an avenue currently only available in all-cash takeovers.The case is the first in which a minority stakeholder has attempted to get a Cayman court to determine the fair value it should receive in an all-share deal, said Tony Heaver-Wren, a partner at Appleby, the Cayman’s oldest law firm.Minority shareholders in cash-rich Global Cord Blood would end up with thinly traded shares with a lower value through the deal with Singapore-listed Cordlife Group Ltd., Jayhawk said in its complaint. Cordlife is partly owned by Global Cord Blood’s majority shareholder.The suit is also seeking to have the three directors removed from a special board committee assessing the offer, claiming they have received “generous compensation” from Global Cord Blood.Global Cord Blood, which is incorporated in the Cayman Islands and listed on the New York Stock Exchange, said it will “vigorously” defend the suit.“The company has reviewed the allegations contained in the summons and believes they are without merit,” Global Cord Blood said in a July 23 regulatory filing. The special committee is still evaluating the proposed merger, it added.The firm’s investor relations department declined to comment further.Global Cord Blood, once known as China Cord Blood, is China’s oldest and largest company that specializes in extracting, processing and storing umbilical cord stem cells that can be used to treat diseases such as leukemia.Shawnee, Kansas-based Jayhawk has been an investor for 12 years and holds an 11% stake.Global Cord Blood shares closed Friday at $5.42 in New York. The stock has fallen 16% this year.Jayhawk alleged a long history of corporate governance lapses at Global Cord Blood. The company twice issued convertible bonds in 2012, even though it didn’t need fresh capital, the hedge fund said in the suit.Minority shareholders were diluted by 50% after the bonds were converted into shares in 2017, in favor of then majority shareholder, Hong Kong-listed Golden Meditech Holdings Ltd., the suit says. Global Cord Blood’s board denied Jayhawk’s requests to buy the convertible bonds alongside Golden Meditech, the fund claimed.The three independent directors -- Mark Chen, Jennifer Weng and Ken Lu -- “have failed to exercise any independence or impartiality in approving the majority shareholders’ self-dealing transactions” in past decade, Jayhawk said in the suit.The trio allowed Golden Meditech to sell its 65% stake at about $11.70 each in January 2018 -- above the share price at the time without giving minority shareholders the same offer, the suit says.Global Cord Blood has accumulated $745 million cash while paying just one cash dividend since 2009, and the directors received restricted stock worth more than $1 million each and sold their holdings in 2017 when the stock price was at a peak, Jayhawk said.To contact the reporter on this story: Bei Hu in Hong Kong at firstname.lastname@example.orgTo contact the editors responsible for this story: Katrina Nicholas at email@example.com, Peter VercoeFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
HONG KONG , July 24, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, ...
NEW YORK, July 17, 2019 /PRNewswire/ -- The Seiden Group, a law firm headquartered in New York, representing a shareholder group of Global Cord Blood Corporation (NYSE: CO) (the "Company" or "Global Cord") has issued a strong second letter today to the Independent Directors of Global Cord due to the lack of response to the first letter sent on June 17, 2019 and rapidly developing events. In the current letter, the Company is urged to take certain actions to uphold their fiduciary duty to protect minority shareholder rights. Abide by basic corporate governance and transparency and announce the names of financial advisors and preserve all instructions in email, including the firms contacted during the "market check" process by the financial advisor.
NEW YORK, NY / ACCESSWIRE / June 19, 2019 / Global Cord Blood Corp. (NYSE: CO ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on June 19, 2019 at 8:00 AM Eastern ...
Added 22,194 New Subscribers in 4Q19 4Q19 Revenues Increased by 8.0% YoY to RMB251.7 Million ( $37.5 Million ) 4Q19 Operating Income Increased to RMB 88.9 Million ($ 13.2 Million) Conference Call to be ...
NEW YORK, June 17, 2019 /PRNewswire/ -- A shareholder of Global Cord Blood Corporation (CO) (the "Company" or "Global Cord") has hired The Seiden Group, a law firm headquartered in New York, as shareholder counsel to communicate minority shareholder interests to the Independent Directors and help effect necessary changes for the benefit of the Company and its shareholders, including minority shareholders in the United States. The Seiden Group issued a letter today to the Independent Directors of Global Cord on behalf of the shareholder making certain requests relating to a potential merger with a Singaporean company and explaining why the deal would harm investors.
Earnings Call Scheduled for 8:00 a.m. ET on June 19, 2019 HONG KONG , June 11, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company") today announced that it plans to release ...
Global Cord Blood Corp NYSE:COView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CO. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $939,705 over the last one-month into ETFs that hold CO are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
HONG KONG, June 6, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding proposal letter dated June 4, 2019 received by the Company's Board of Directors (the "Board") from Cordlife Group Limited ("Cordlife"), a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife proposes to combine the businesses of Cordlife and the Company by way of a statutory merger, the Board has formed a special committee of independent directors who are not affiliated with Cordlife (the "Special Committee") to evaluate such proposal. The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu and Ms. Jennifer J. Weng, each of whom currently serves as an independent director on the Board, with Mr. Chen serving as the chair of the Special Committee.
HONG KONG, June 4, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors has received a non-binding proposal letter from Cordlife Group Limited ("Cordlife"), a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife proposes to combine the businesses of Cordlife and the Company, by way of a statutory merger.
ASICS and ASICS RUNKEEPER community to share the ups (and downs) we've had with our shoes with #DearShoes social media giveaway, in-app run challenge and nearly 50 in-store events across the U.S. BOSTON, June 3, 2019 /PRNewswire/ -- ASICS, the true sport performance brand, and ASICS Runkeeper™ app are celebrating Global Running Day in the United States with a nationwide activation that gives runners and run lovers a platform to share why they love the pastime. With a deep history rooted in running, ASICS is at the core of many stories that describe the passion behind a run.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of December. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
HONG KONG, April 1, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company is increasing its processing fee by RMB3,000 to RMB9,800, effective on April 1, 2019. The Company's annual storage fee is unaffected by this increase. The Company is committed to delivering high quality and top of the line services to all clients, and this is evidenced by the Company's continuous investment in cord blood banking hardware as well as software.